Uranium Royalty Corp. shares rise 5.26% intraday after Royalty Pharma acquires royalty interest in Amgen's Imdelltra.

Uranium Royalty Corp. rose 5.26% intraday, with the company's stock price increase potentially influenced by the recent acquisition of a royalty interest in Amgen's Imdelltra by Royalty Pharma. This acquisition, valued at $885 million upfront, includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million within the next 12 months. Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for the treatment of extensive-stage small cell lung cancer, affecting approximately 360,000 patients worldwide each year.